Is tesamorelin FDA approved? Status, evidence and what the label actually says

The short version. Tesamorelin is an FDA approved drug, sold as Egrifta, to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. Its own label says it is not for weight loss. The trial evidence is real and specific to that population: the largest trials enrolled 412 and 404 patients. Nothing in the approval covers healthy adults, body composition or anti-ageing.

What is tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone, described in the 2010 pooled analysis in the Journal of Clinical Endocrinology and Metabolism as GHRH(1-44). It works upstream of growth hormone: it acts on pituitary cells to stimulate release of the body's own growth hormone rather than supplying growth hormone itself. In the phase 3 program, that raised IGF-1, the marker of growth hormone activity, by 81% in the first trial published in the New England Journal of Medicine. That is also why the label carries a warning on elevated IGF-1, and why the drug is a hormonal agent with a specific medical use rather than a general supplement.

Is tesamorelin FDA approved, and for what?

Tesamorelin has a clear approval record, which is what separates it from most peptides sold alongside it. Drugs@FDA lists Egrifta under application 022505, approved 10 November 2010, and records that the application was deemed a biologics license application on 23 March 2020. The most recent supplement on that record was approved 25 March 2025, the month the Egrifta WR formulation was approved.

The sentence to read twice is the limitation of use. The label does not say weight loss is unproven for tesamorelin. It says the drug is not indicated for weight loss management as it has a weight neutral effect. A page that treats tesamorelin as a fat-loss compound for the general public is describing a claim the manufacturer's own approved label rules out.

In plain EnglishApproved for one group of patients, for one purpose. Anyone selling it as a general fat-loss or anti-ageing product is describing something the label does not say.

The tesamorelin label says the drug has a weight neutral effect. It is approved to reduce one kind of fat in one group of patients.

What is tesamorelin's legal status in 2026?

Tesamorelin's legal position is different from BPC-157 or TB-500, because it is an approved product with a marketed brand. What this file can report from primary sources is limited. The FDA's page on bulk drug substances used in compounding under section 503A, updated 14 May 2026, does not name tesamorelin. We found no FDA statement on compounded tesamorelin in this review, and we do not offer a legal conclusion on it. Because Egrifta is regulated as a biologic, the compounding question is one for a licensed pharmacist or lawyer, not for a website that sells the product.

The Ozemback peptide legal status tracker lists tesamorelin as approved, and it was not among the peptides the FDA advisory committee reviewed in July 2026. That vote changed nothing about tesamorelin, whatever pages selling it may imply. For the question of why the doses quoted online differ from the label, see our analysis of the top three search results.

What does the evidence for tesamorelin show?

The evidence base is two phase 3 trials of about 400 patients each, in HIV-infected adults on antiretroviral therapy, with a 26-week placebo comparison and a 26-week extension.

The first trial, published by Falutz and colleagues in the New England Journal of Medicine in December 2007, randomised 412 patients with HIV and abdominal fat accumulation to 2 mg of tesamorelin or placebo daily for 26 weeks. Visceral adipose tissue measured by CT fell 15.2% in the tesamorelin group and rose 5.0% in the placebo group. Triglycerides fell 50 mg per deciliter against a 9 mg rise, and the ratio of total cholesterol to HDL cholesterol fell 0.31 against a 0.21 rise (P less than 0.001 for all). IGF-1 rose 81.0%. Adverse events did not differ significantly, although more patients on tesamorelin withdrew because of one, and glycemic measures showed no significant differences.

The 2010 pooled analysis of both phase 3 trials covered 806 patients, 543 on tesamorelin and 263 on placebo. At week 26, visceral fat fell 24 cm² against a 2 cm² rise (treatment effect, -15.4%), while abdominal subcutaneous fat did not change significantly (treatment effect, -0.6%). In the group that continued tesamorelin for the 26-week extension, the visceral fat reduction was maintained at week 52. A 2012 analysis in Clinical Infectious Diseases found that patients whose visceral fat fell 8% or more had better triglyceride and glucose-related outcomes than those whose fat did not, and it was a post hoc comparison, not a randomised one.

In plain EnglishIn people with HIV who had built up belly fat on their treatment, the drug shrank the deep abdominal fat while the fat under the skin stayed put. The same group on placebo saw that deep fat grow. That is the whole result, and it applies to that group.

What has been reported on safety

The Egrifta WR label lists arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema and myalgia as the most common adverse reactions, at 5% or more. Its warnings cover increased risk of neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes mellitus, hypersensitivity reactions, injection site reactions and increased mortality in patients with acute critical illness. It is contraindicated with disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity and pregnancy. The label also states that long-term cardiovascular safety has not been established. Those are the warnings for the approved population under medical supervision.

What is the approved dose of tesamorelin?

The recommended dose depends on the formulation, and the label says the formulations are not substitutable. No dose is approved for anyone outside the HIV lipodystrophy indication.

The Egrifta WR label states a recommended dosage of 1.28 mg subcutaneously once daily, injected into the abdomen with rotating sites, for the approved indication. The pivotal trials described above used 2 mg once daily of the original formulation, which is a different product. The label also says to consider discontinuing treatment in patients with persistent IGF-1 elevations, particularly if the response is not robust. We report the label because it is the record. Figures on pages that rank for tesamorelin dosage often mix formulations, and many of those pages sell the product or a consultation. We do not publish a recommended dose or protocol for this or any compound.

What is still unknown about tesamorelin?

• Whether it does anything useful outside HIV lipodystrophy. The controlled trials enrolled HIV-infected adults on antiretroviral therapy. We reviewed no trial of comparable size in other populations.
• Long-term cardiovascular and cancer safety. The label says long-term cardiovascular safety is not established and carries a neoplasm warning.
• What happens after treatment stops. The trials ran 26 weeks with a 26-week extension. This file does not report longer follow-up.
• Whether raising IGF-1 is safe over years in healthy people. The label treats elevated IGF-1 as a warning in the approved population.
• Whether the FDA will say anything about compounded tesamorelin. We found no statement in this review.

How should you read other pages about tesamorelin?

Check that the page names the formulation next to every dose, because Egrifta WR and Egrifta SV are not substitutable. Check that it says the approval is for HIV-associated lipodystrophy only and that the label rules out weight loss. Check who pays the author: nearly every site ranking for tesamorelin dosage or results sells it, prescribes it or sells a consultation leading to it. This page carries a date at the top, 29 September 2026, so you can tell when it stops being current.

The questions people actually type

Sources